



Reena Thomas, MD PhD

- Clinical Professor, Adult Neurology
- Clinical Professor (By courtesy), Neurosurgery

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center Neuro Oncology**

875 Blake Wilbur Dr Rm CC2221

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-3556

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Maribel Tapia - Executive Associate

Email mgtapia@stanford.edu

Bio

BIO

Dr. Reena Thomas, MD, PhD, is a Clinical Professor in Neuro Oncology at Stanford Medicine leading a translational research team in immune-based therapy for cancer. Holding dual degrees in medicine and molecular immunology, Dr. Thomas has worked for more than two decades to integrate clinical expertise with a deep understanding of cellular immunotherapy mechanisms and burgeoning technologies such as CAR-T (Chimeric Antigen Receptor T lymphocyte) cell therapy. These scientific advancements center foremost on improving outcomes for her patients with central nervous system tumors and all those impacted by neurologic complications of cancer.

As a leader in translational research, Dr. Thomas secured a \$12 million award in 2023 to spearhead CAR-T cell therapy innovation for glioblastoma brain tumors, working with her team to revolutionize treatment possibilities and outcomes for patients. She brings more than a decade of experience serving as principal investigator on several NIH funded research programs and trials including a study that established the new standard of care for using checkpoint inhibitor immune therapy for melanoma brain metastasis. Her dedication to advancing medical knowledge is grounded in providing hope to families and bringing her diverse lived experience and scientific accomplishments to bear in the fight against cancer.

In parallel to ongoing research efforts, Dr. Thomas has embraced leadership roles in medical education. As the Fellowship Program Director and Education Chief for Neuro-Oncology at Stanford Medicine, Dr. Thomas mentored and trained the next generation of neuro-oncology specialists, fostering a culture of excellence in both clinical care and research. Her commitment to medical education expanded through subsequent roles as Associate Dean and most recently Senior Associate Dean of Medical Education for Stanford Medicine. In these positions, Dr. Thomas has worked to enhance curriculum design, integrate cutting-edge research into clinical training, and promote interdisciplinary collaboration, ensuring that our trainees are well-equipped to lead the future of academic medicine and beyond.

Dr. Thomas' administrative experience has enabled her to build collaborative teams, secure research funding, and manage large-scale, multi-institutional research programs. Additionally, her deep involvement in education has provided her with valuable perspectives on how to mentor young scientists and clinicians, helping them to navigate the complex intersections of patient care, research, and academic development. This commitment to continuing the

pursuit of groundbreaking discoveries in brain tumor immunology while shaping the academic and clinical leaders of tomorrow is the driving force of her career in medicine.

CLINICAL FOCUS

- Neuro Oncology
- Neurology
- Immunotherapy
- Immuno Oncology
- Primary Brain Tumors
- Metastatic Cancer to CNS
- Neuro-Oncology

ACADEMIC APPOINTMENTS

- Clinical Professor, Adult Neurology
- Clinical Professor (By courtesy), Neurosurgery
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Adult Neuro Oncology Fellowship Program Director, Stanford Hospital, (2014-2021)
- Education Chief of Neuro Oncology, Department of Neurology, (2017-2020)
- Director of Diversity and Inclusion, Department of Neurology, (2017-2021)
- Associate Dean, Diversity in Medical Education, Stanford School of Medicine, (2020-2024)
- Vice Chair, Diversity and Inclusion, Department of Neurology, (2021-2024)
- Senior Associate Dean of Medical Education, Stanford School of Medicine, (2024- present)

HONORS AND AWARDS

- Graduating Resident Teaching Award, Stanford Neurology (July 2013)
- Silicon Valley Top 40 under 40, Silicon Valley Business Journal (December 2014)
- SPARK Fellow, Stanford University (2015)
- Stanford Faculty Fellow, Hispanic Center of Excellence (2015, 2018)
- Mentor of the Year, 1st Gen Mentorship Program, Stanford School of Medicine (November 2018)
- Fellow of the American Academy of Neurology (FAAN), American Academy of Neurology (2024)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Academy of Neurology (2010 - present)
- Member, Society for Neuro Oncology (2011 - present)
- Member, Stanford Society of Physician Scholars (2011 - present)
- Board Certified, American Board of Psychiatry and Neurology (2014 - present)
- Member, American Society of Clinical Oncology (2015 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine (2014) CA

- Residency: Stanford University School of Medicine (2013) CA
- Internship: Georgetown University School of Medicine (2010) DC
- Medical Education: Georgetown University School of Medicine (2009) DC
- BA, Cornell University , Biology; Neurobiology and Behavior (2002)
- PhD, City of Hope Graduate School of Biological Sciences, City of Hope Cancer Center , Molecular Immunology (2006)
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2014)

COMMUNITY AND INTERNATIONAL WORK

- Faculty Mentor

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>
- Stanford Neuro Oncology: <http://med.stanford.edu/neurology/divisions/neurooncology.html>
- Stanford Medicine, Dean's Office: <https://med.stanford.edu/school/leadership/sr-assoc-deans.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

-Neuro Oncology Immunotherapy

-Medical Education

CLINICAL TRIALS

- Phase I B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme, Recruiting
- Phase I/II Panitumumab-IRDye800 Optical Imaging Agent to Detect Neoplasms in Neurosurgical Procedures, Recruiting
- INO-5401 & INO-9012 Delivered by Electroporation(EP) +REGN2810 in Newly-Diagnosed Glioblastoma (GBM), Not Recruiting
- Lactate and Bicarbonate Detection Within Malignant Brain Tumors Using [1-13C]-Pyruvate DNP MRS, Not Recruiting
- Phase I 1st-In-Human REGN2810 Programmed Death-1 Tx +/-Other Anti-Cancer Tx in Advanced Malignancies, Not Recruiting
- Phase I [18F]DASA-23 PET Tracer to Evaluate Pyruvate Kinase M2 Expression in Intracranial Tumors &HV, Not Recruiting
- Phase I BPM31510 +Vitamin K in High-Grade Glioma that has Recurred on Bevacizumab Containing Regimen, Not Recruiting
- Phase Ib/II ACP-196 in Recurrent Glioblastoma Multiforme (GBM), Not Recruiting
- Phase II F-U Whole Brain RT (WBRT) + Temozolomide Chemo-RT in Glioblastoma(GBM) Following Plerixafor, Not Recruiting
- Phase II in Metastatic Brain Melanoma treated w/ Nivolumab + Ipilimumab followed by Nivolumab MonoTx, Not Recruiting
- Phase II ONC201 in Recurrent High-Grade Glioma, Not Recruiting
- Phase II/III Toca 511 + Toca FC vs SoC in Recurrent Glioblastoma or Anaplastic Astrocytoma Resection, Not Recruiting
- Phase III ICT-107 +Temozolomide(TMZ) in Glioblastoma After Resection &Concomitant TMZ ChemoradioTx, Not Recruiting
- Phase III Memantine & Whole-Brain Radiotherapy +/- Hippocampal Avoidance in Brain Metastases, Not Recruiting
- Phase III VB-111 + Bevacizumab vs Bevacizumab Monotherapy in Recurrent Glioblastoma, Not Recruiting

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Akshay Swaminathan

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE**
Chen, Y., Song, K., Desai, M., Ehlinger, Z., Daghigh, H., Rietberg, S., Feeney, A., Tanner, K., Dyson, K., Stockdale, B., Dhapola, G., Lohman, C., Patil, et al
OXFORD UNIV PRESS INC.2025: v13
- **EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING**
Dyson, K., Zuraski, C., Solomon, D., Li, G., Stocksdales, B., Song, K., Mahdi, J., Tanner, K., Bertrand, S., Iv, M., Threlkeld, Z., Ramakrishna, S., Sahaf, et al
OXFORD UNIV PRESS INC.2025: v49-v50
- **Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.** *Cancer reports (Hoboken, N.J.)*
Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, et al
2025; 8 (9): e70330
- **A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.**
Li, G., Stocksdales, B. R., Song, K., Mahdi, J., Tanner, K., Bertrand, S., Iv, M., Threlkeld, Z., Ramakrishna, S., Sahaf, B., Egeler, E., Charu, V., Tunuguntla, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: 2018
- **Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.**
Sumrall, A., Allen, J. E., Bagley, S., Brundage, T., Butowski, N. A., Clymer, J., Haggiagi, A., Koschmann, C., Kurz, S., Macdonald, T. J., Majd, N., Mueller, S., Ramage, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **From conference to career: Tracing medical pathways of Stanford university's minority medical alliance (SUMMA) premedical conference alumni.** *Journal of the National Medical Association*
Gonzalez-Suarez, A. D., Moya, E., Perez, F. D., Gutierrez, M., Thomas, R. P.
2025
- **Understanding Diversity, Equity, and Inclusion Roles in Academic Neurology Departments.** *Neurology*
Spector, A. R., Mohile, N. A., Chadehumbe, M., Croff, R., Flippen li, C. C., Gutierrez, C. A., Hamilton, R. H., Leacock, R., Monteith, T. S., O'Carroll, C., Rutatangwa, A., Thomas, R. P.
2024; 103 (10): e209989
- **Underrepresented in Medicine Trainees' Sense of Belonging and Professional Identity Formation after Participation in the Leadership Education in Advancing Diversity Program.** *Academic pediatrics*
Yemane, L., Powell, C., Edwards, J., Shumba, T., Alvarez, A., Bandstra, B., Brooks, M., Brown-Johnson, C., Caceres, W., Dunn, T., Johnson, C., Perez, F. D., Reece-Nguyen, et al
2024
- **Extraction of Unstructured Electronic Health Records to Evaluate Glioblastoma Treatment Patterns.** *JCO clinical cancer informatics*
Swaminathan, A., Ren, A. L., Wu, J. Y., Bhargava-Shah, A., Lopez, I., Srivastava, U., Alexopoulos, V., Pizzitola, R., Bui, B., Alkhani, L., Lee, S., Mohit, N., Seo, et al
2024; 8: e2300091
- **A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma**
Cao, T., Gu, Y., Yagmurlu, B., Yerraballa, H., Bertrand, S., Naya, L., Miller, K., Iv, M., Soltys, S. G., Patel, C. B., Nagpal, S., Thomas, R., Brown, et al
LIPPINCOTT WILLIAMS & WILKINS.2024

- **Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.** *The neuroradiology journal*
Iv, M., Naya, L., Sanan, S., Van Buskirk, S. L., Nagpal, S., Thomas, R. P., Recht, L. D., Patel, C. B.
2023: 19714009231207083
- **Selective prediction for extracting unstructured clinical data.** *Journal of the American Medical Informatics Association : JAMIA*
Swaminathan, A., Lopez, I., Wang, W., Srivastava, U., Tran, E., Bhargava-Shah, A., Wu, J. Y., Ren, A. L., Caoili, K., Bui, B., Alkhani, L., Lee, S., Mohit, et al
2023
- **Patterns of Progression in Patients with Newly Diagnosed Glioblastoma Treated with 5 mm Margins on a Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery with Concurrent and Adjuvant Temozolomide.** *Practical radiation oncology*
Mendoza, M. G., Azoulay, M., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., Adler, J. R., Harraher, C., Li, G., Gephart, M. H., Nagpal, S., Thomas, R. P., Recht, et al
2023
- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.** *The Neurohospitalist*
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.
2023; 13 (1): 53-60
- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy** *NEUROHOSPITALIST*
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.
2022
- **Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.** *Practical radiation oncology*
Halasz, L. M., Attia, A., Bradfield, L., Brat, D. J., Kirkpatrick, J. P., Laack, N. N., Lalani, N., Lebow, E. S., Liu, A. K., Niemeier, H. M., Palmer, J. D., Peters, K. B., Sheehan, et al
2022
- **Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors.** *Cancers*
Jin, M. C., Hsin, G., Ratliff, J., Thomas, R., Zygourakis, C. C., Li, G., Wu, A.
2022; 14 (10)
- **A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., Reyes, S. T., Phillips, M., Buccino, P., Shen, B., Park, J. H., Koran, M. E., Alam, et al
2021
- **EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.** *Theranostics*
Zhou, Q., van den Berg, N. S., Rosenthal, E. L., Iv, M., Zhang, M., Vega Leonel, J. C., Walters, S., Nishio, N., Granucci, M., Raymundo, R., Yi, G., Vogel, H., Cayrol, et al
2021; 11 (15): 7130-7143
- **Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).** *Neuro-oncology*
Tawbi, H. A., Forsyth, P. A., Hodi, F. S., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K., Thomas, R. P., Glaspy, J. A., Jang, S., Algazi, A. P., Khushalani, et al
2021
- **Developing the Neurology Diversity Officer: A Roadmap for Academic Neurology Departments.** *Neurology*
Mohile, N. A., Spector, A. R., Ebong, I. M., Flippen, C. 2., Gutierrez, C., Leacock, R. O., Marulanda-Londono, E., Mejia, N. I., Thomas, R., Hamilton, R. H.
2021
- **Outcomes From a Novel Graduate Medical Education Leadership Program in Advancing Diversity, Equity, and Inclusion** *Journal of Graduate Medical Education*
Powell, C., Yemane, L., Brooks, M., Johnson, C., Alvarez, A., Bandstra, B., Caceres, W., Dierickx, Q., Thomas, R., Blankenburg, R.

2021; 13 (6): 774–784

- **Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.** *The Lancet. Oncology*
Tawbi, H. A., Forsyth, P. A., Hodi, F. S., Algazi, A. P., Hamid, O., Lao, C. D., Moschos, S. J., Atkins, M. B., Lewis, K., Postow, M. A., Thomas, R. P., Glaspy, J., Jang, et al
2021
- **EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial** *Theranostics*
Zhou, Q., van den Berg, N. S., Rosenthal, E. L., Iv, M., Zhang, M., Vega Leonel, J. C., Walters, S., Nishio, N., Granucci, M., Raymundo, R., Yi, G., Vogel, H., Cayrol, et al
2021; 11 (15): 7130-7143
- **Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy** *The Neurohospitalist*
Reveron-Thornton, R., Scott, B. J., Post, D., Finley Caulfield, A., Werbaneth, K., Hovsepian, D. A., Spiegel, J., Miklos, D., Thomas, R. P., Patel, C. B.
2021: 74-79
- **Phase I study of BPM31510 and vitamin K in patients with high grade glioma recurrent after a bevacizumab-containing regimen.**
Nagpal, S., Thomas, R., Bertrand, S., Yerraballa, H., Iv, M., Li, G., Klotz, A., Kiebish, M. A., Narain, N. R., Sarangarajan, R., Granger, E., Recht, L.
AMER SOC CLINICAL ONCOLOGY.2020
- **Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.** *Journal of neuro-oncology*
Shi, S., Jaoube, J. A., Kanwar, R., Jin, M. C., Amarin, A., Varanasi, V., Eisinger, E., Thomas, R., Moore, J. M.
2020
- **A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.** *Neuro-oncology*
Azoulay, M. n., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., Harsh, G. R., Adler, J. R., Harrahar, C. n., Li, G. n., Hayden Gephart, M. n., Nagpal, S. n., Thomas, R. P., Recht, et al
2020
- **Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.** *World neurosurgery*
Zhang, M. n., Rodrigues, A. J., Bhambhani, H. P., Fatemi, P. n., Pollom, E. L., Gibbs, I. C., Thomas, R. P., Soltys, S. G., Hancock, S. L., Chang, S. D., Reddy, S. A., Gephart, M. H., Li, et al
2020
- **Impact of the Patient Protection and Affordable Care Act on 1-year survival in glioblastoma patients.** *Neuro-oncology advances*
Moghavem, N., Oh, D. L., Santiago-Rodriguez, E. J., Tate, W. J., Gomez, S. L., Thomas, R.
2020; 2 (1): vdaa080
- **Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.** *Frontiers in oncology*
Jin, M. C., Liu, E. K., Shi, S. n., Gibbs, I. C., Thomas, R. n., Recht, L. n., Soltys, S. G., Pollom, E. L., Chang, S. D., Hayden Gephart, M. n., Nagpal, S. n., Li, G. n.
2020; 10: 337
- **Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Brown, J. M., Thomas, R., Nagpal, S., Recht, L.
2019; 144: 159–64
- **EVALUATION OF [18F]DASA-23 FOR NON-INVASIVE MEASUREMENT OF ABERRANTLY EXPRESSED PYRUVATE KINASE M2 IN GLIOMA: FIRST-IN-HUMAN STUDY**
Patel, C., Beinat, C., Haywood, T., Murty, S., Xie, Y., Recht, L., Nagpal, S., Thomas, R., Khalighi, M., Gandhi, H., Holley, D., Gambhir, S.
OXFORD UNIV PRESS INC.2019: 169
- **A PHASE 1 STUDY OF BPM31510 PLUS VITAMIN K IN SUBJECTS WITH HIGH-GRADE GLIOMA THAT HAS RECURRENTED ON A BEVACIZUMAB-CONTAINING REGIMEN**
Recht, L., Thomas, R., Bertrand, S., Yerballa, P., Li, G., Iv, M., Narain, N., Sarangarajan, R., Granger, E., Nagpal, S.
OXFORD UNIV PRESS INC.2019: 27

- **Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)**
Tawbi, H., Forsyth, P., Hodi, F., Lao, C., Moschos, S., Hamid, O., Atkins, M. B., Lewis, K., Thomas, R. P., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, et al
NATURE PUBLISHING GROUP.2019: 20
- **Rooting out racial stereotypes in Neurology (R) A commentary on "Lucky and the root doctor" NEUROLOGY**
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al
2019; 92 (22): 1029–32
- **Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).**
Tawbi, H., Forsyth, P. A. J., Hodi, F., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K. D., Thomas, R., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Rooting out racial stereotypes in Neurology: A commentary on "Lucky and the root doctor". Neurology**
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L. 4., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al
2019
- **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities PIGMENT CELL & MELANOMA RESEARCH**
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. K. C., Chen, et al
2019; 32 (3): 458–69
- **EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome**
Satyanarayan, S., Markert, M., Hovsepian, D., Post, D., Muffly, L., Miklos, D., Thomas, R., Scott, B.
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Neurological Adverse Effects Due to Programmed Death (PD-1) Inhibitors**
Shi, S., Kanwar, R., Varanasi, V., Eisinger, E., Thomas, R., Moore, J.
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment cell & melanoma research**
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. K., Ann Chen, et al
2019
- **Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Post-Resection Stereotactic Radiosurgery for Brain Metastases: A Multi-Institutional Study of Inter-Observer Reliability. International journal of radiation oncology, biology, physics**
Turner, B. E., Prabhu, R. S., Burri, S. H., Brown, P. D., Pollom, E. L., Milano, M. T., Weiss, S. E., Iv, M. n., Fischbein, N. n., Soliman, H. n., Lo, S. S., Chao, S. T., Cox, et al
2019
- **Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making. AJNR. American journal of neuroradiology**
Iv, M. n., Liu, X. n., Lavezo, J. n., Gentles, A. J., Ghanem, R. n., Lummus, S. n., Born, D. E., Soltys, S. G., Nagpal, S. n., Thomas, R. n., Recht, L. n., Fischbein, N. n.
2019
- **Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research**
Thomas, R. P., Nagpal, S. n., Iv, M. n., Soltys, S. G., Bertrand, S. n., Pelpola, J. S., Ball, R. L., Yang, J. n., Sundaram, V. n., Lavezo, J. L., Born, D. E., Vogel, H. n., Brown, et al
2019
- **Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England journal of medicine**
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, et al

2018; 379 (8): 722–30

- **Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study.** *Radiology*
Iv, M. n., Samghabadi, P. n., Holdsworth, S. n., Gentles, A. n., Rezaii, P. n., Harsh, G. n., Li, G. n., Thomas, R. n., Moseley, M. n., Daldrup-Link, H. E., Vogel, H. n., Wintermark, M. n., Cheshier, et al
2018: 181204
- **Conditional Probability of Survival as a Proposed Endpoint for Future Single-Arm Clinical Trials in Glioblastoma**
Patel, C. B., Thomas, R. P., Nagpal, S., Recht, L. D.
WILEY.2017: S206–S207
- **Anti-PD-1-associated inflammatory-demyelinating lesions in patients with brain metastases**
Samghabadi, P., Makar, S., Thomas, R., Pelpola, J., Reddy, S., Tranvinh, E., Spence, A., Vogel, H., Born, D., Sobel, R.
OXFORD UNIV PRESS INC.2017: 500–501
- **Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.** *International journal of radiation oncology, biology, physics*
Pollom, E. L., Fujimoto, D., Wynne, J., Seiger, K., Modlin, L. A., Jacobs, L. R., Azoulay, M., von Eyben, R., Tupper, L., Gibbs, I. C., Hancock, S. L., Li, G., Chang, et al
2017; 98 (1): 123-130
- **Response of metastatic glioma to vemurafenib.** *Neuro-oncology practice*
Leaver, K. E., Zhang, N., Ziskin, J. L., Vogel, H., Recht, L., Thomas, R. P.
2016; 3 (4): 268-271
- **Melanoma central nervous system metastases: current approaches, challenges, and opportunities** *PIGMENT CELL & MELANOMA RESEARCH*
Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V. L., de Groot, J., Glitza, I. C., Herlyn, M., Holmen, S. L., Jilaveanu, L. B., Lassman, et al
2016; 29 (6): 627-642
- **Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma** *JOURNAL OF NEURO-ONCOLOGY*
Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., Pena, J., Gershon, M., Coffey, G., Kunz, P. L., Li, G., Recht, L. D.
2015; 123 (2): 277-282
- **Treatment options for optic pathway gliomas.** *Current treatment options in neurology*
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.
2015; 17 (2): 333-?
- **Treatment Options for Optic Pathway Gliomas** *CURRENT TREATMENT OPTIONS IN NEUROLOGY*
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.
2015; 17 (2)
- **ARE WE USING TOO MUCH BEVACIZUMAB IN OUR GBM PATIENTS?**
Ajlan, A., Thomas, P., Thomas, R., Nagpal, S., Recht, L.
OXFORD UNIV PRESS INC.2014
- **COMPLETE RESPONSE TO VEMURAFINIB IN A PATIENT WITH METASTATIC ANAPLASTIC XANTHROASTROCYTOMA**
Thomas, R., Ajlan, A., Ziskin, J., Soltys, S., Reddy, S., Recht, L., Nagpal, S.
OXFORD UNIV PRESS INC.2014
- **Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI.** *Journal of cerebral blood flow and metabolism*
Schmiedeskamp, H., Andre, J. B., Straka, M., Christen, T., Nagpal, S., Recht, L., Thomas, R. P., Zaharchuk, G., Bammer, R.
2013; 33 (5): 732-743
- **The incidence and significance of multiple lesions in glioblastoma** *JOURNAL OF NEURO-ONCOLOGY*
Thomas, R. P., Xu, L. W., Lober, R. M., Li, G., Nagpal, S.
2013; 112 (1): 91-97

- **Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.** *Clinical pharmacology : advances and applications*
Thomas, R. P., Recht, L., Nagpal, S.
2013; 5: 1-9
- **PRELIMINARY RESULTS UTILIZING VESSEL SIZE IMAGING AS A METRIC OF RESPONSE IN GLIOBLASTOMA MULTIFORME** *17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)*
Andre, J. B., Schmiedeskamp, H., Thomas, R. P., Feroze, A., Nagpal, S., Zaharchuk, G., Straka, M., Recht, L., Bammer, R.
OXFORD UNIV PRESS INC.2012: 127–127
- **THE INCIDENCE AND SIGNIFICANCE OF MULTIPLE LESIONS IN GLIOBLASTOMA**
Xu, L. W., Thomas, R. P., Lober, R. M., Nagpal, S., Li, G.
OXFORD UNIV PRESS INC.2012: 120
- **Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells** *JOURNAL OF IMMUNOLOGY*
Brown, C. E., Vishwanath, R. P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K. S., Jensen, M. C.
2007; 179 (5): 3332-3341
- **A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells** *JOURNAL OF IMMUNOLOGICAL METHODS*
Vishwanath, R. P., Brown, C. E., Wagner, J. R., Meechoovet, H. B., Naranjo, A., Wright, C. L., Olivares, S., Qian, D., Cooper, L. J., Jensen, M. C.
2005; 302 (1-2): 78-89
- **Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing** *JOURNAL OF IMMUNOLOGICAL METHODS*
Brown, C. E., Wright, C. L., Naranjo, A., Vishwanath, R. P., Chang, W. C., Olivares, S., Wagner, J. R., Bruins, L., Raubitschek, A., Cooper, L. J., Jensen, M. C.
2005; 297 (1-2): 39-52
- **Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products** *JOURNAL OF CLINICAL LABORATORY ANALYSIS*
Juhasz, A., Frankel, P., Cheng, C., Rivera, H., Vishwanath, R., Chiu, A., Margolin, K., Yen, Y., Newman, E. M., Synold, T., Wilczynski, S., Lenz, H. J., Gandara, et al
2003; 17 (5): 184-194